For example, allovectin-7
(a plasmid/ lipid complex with DNA sequences encoding HLA-B7 and B2 microglobulin) induces a 5-fold increase in the frequency of HLA-B7 cytotoxic T cells, upregulates/restores MHC-1 molecules, and induces a proinflammatory response.
These vaccines include Allovectin-7
and OncoVEX, for the treatment of Melanoma, BiovaxId (Idiotype vaccine therapy) for follicular non-Hodgkin lymphoma, and GV1001 for advanced pancreatic cancer.
A Phase 3 pivotal trial comparing Allovectin-7
The drug, Allovectin-7, is currently in a late-stage trial through a Special Protocol Assessment agreement with the U.S.
The company said a mid-stage trial of the drug has found that patients who received high-dose Allovectin-7 had a median survival of 18.8 months.
(Vical) today announced the start of phase III of their clinical trial of Allovectin-7
-a gene therapy treatment drug for progressive melanoma patients.
MINNEAPOLIS -- Interim results from a phase II trial indicate that Allovectin-7
is an active, well-tolerated treatment for advanced metastatic melanoma patients, Dr.
The new patent covers a range of applications of the company's core DNA delivery technology, including cationic lipid-formulated, gene-based immunotherapeutics such as Vical's clinical-stage Allovectin-7
treatment for melanoma, cationic lipid-formulated DNA vaccines such as Vical's developmental anthrax vaccine, and similar pharmaceutical products under development by others.
29 January 2010 - US biopharmaceutical products maker Vical Incorporated (NASDAQ: VICL) said yesterday it has completed enrollment of the planned 375 subjects in its Phase III trial of Allovectin-7
in patients with metastatic melanoma.
Tokyo, Japan, May 30, 2006 - (JCN) - AnGes MG announced on May 30 that it has signed a collaboration agreement with US bio venture company Vical for Allovectin-7
, Vical's proprietary immunotherapeutic for malignant melanoma.
Vical's two lead product candidates, Allovectin-7
and Leuvectin, both involve direct injection of genetic material into tumors or surrounding tissue using lipids to facilitate delivery.
28 December 2009 - US-based biopharmaceutical products developer Vical Incorporated (NASDAQ: VICL) said today that an independent Safety Monitoring Board (SMB) for its Phase III AIMM trial of Allovectin-7
in patients with metastatic melanoma has completed the trial's third scheduled safety analysis and recommended that the study continue per the protocol.